GlassScriptPhysician profile
John Roefs
NPI 1699820688
$3,435.81
in general payments reported to CMS, 2019-2025
11 companies · $264 in 2025
The $264 reported for 2025 was less than what a typical Neuroradiology provider received nationally (typical 2025 total: $278).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $100 · 2022: $1,388 · 2023: $943 · 2024: $520 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $2,450.37 | 2022-2025 | Indigo System, Penumbra System, Ruby Coil |
| Inari Medical, INC. | $599.18 | 2020-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Stryker Corporation | $113.38 | 2025 | Clottriever Bold Catheter, Flowtriever |
| Cook Medical LLC | $50.85 | 2024-2025 | Cook Celect, Cook |
| Incyte Corporation | $46.95 | 2019 | |
| Dendreon Pharmaceuticals LLC | $45.14 | 2019 | |
| Eisai INC. | $39.25 | 2019 | |
| Puma Biotechnology, INC. | $31.92 | 2019 | |
| Tesaro, INC. | $22.34 | 2019 | |
| Aurobindo Pharma USA, INC. | $19.62 | 2019 | |
| Daiichi Sankyo INC. | $16.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Roefs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.